Results 281 to 290 of about 1,004,201 (343)

Analysis of C4 Concentrations to Predict Impact of Patient‐Reported Diarrhea Associated With the Ileal Bile Acid Transporter Inhibitor Linerixibat

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 596-605, March 2025.
ABSTRACT Linerixibat, an ileal bile acid transporter (IBAT) inhibitor, is being evaluated for the treatment of pruritus in primary biliary cholangitis (PBC). Diarrhea is commonly reported with this drug class as IBAT inhibition redirects bile acids (BA) to the colon.
Fernando Carreño   +4 more
wiley   +1 more source

Comparison of monotherapy and combination therapy for older patients with advanced biliary tract cancer: a retrospective study. [PDF]

open access: yesBMC Cancer
Oishi R   +7 more
europepmc   +1 more source

Report from the 26th Annual Western Canadian Gastrointestinal Cancer Consensus Conference on Hepatocellular and Biliary Tract Cancer, Saskatoon, Saskatchewan, 17-18 October 2024. [PDF]

open access: yesCurr Oncol
Ravi D   +22 more
europepmc   +1 more source

Diffuse hepatic hemangiomatosis of radial growth: A rare manifestation

open access: yesAsian Journal of Surgery
Rui-Qi Zou   +3 more
doaj  

Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract Cancer. [PDF]

open access: yesClin Cancer Res
DiPeri TP   +20 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy